LONDON, UK / ACCESSWIRE / January 11, 2021 / Carmat announced that it has received a CE Mark for its physiologic heart replacement therapy (PHRT) and that the product will be launched in Q221 under the brand name Aeson. The approved indication is a bridge to transplantation therapy (BTT), although over time we expect approval for Aeson as a destination therapy (DT), which will enable commercialisation to a larger number of patients. The initial commercial focus will be on France and Germany, which Carmat estimates to account for 55% of the EU mechanical circulatory support market.
We have increased our valuation to €747m or €58.83 per share from €679m or €53.88 per share. This is mostly due to our increase in the probability of commercial success for Aeson in the EU to 35% from 30% following receipt of the CE Mark. This was partially offset by more conservative near-term estimates as the launch will occur later in 2021 than expected and is also more focused. We assume a financing requirement of €40m for 2021 to fund US clinical development and the commercial launch.
Click here to view the full report.
Subscribe to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Maxim Jacobs, +1 646 653 7027
Nathaniel Calloway, +1 646 653 7036
SOURCE: Edison Investment Research Limited
View source version on accesswire.com: